Li X, Syed I, Zhang Z, Adhikari R, Tang D, Ko S
bioRxiv. 2024; .
PMID: 39553957
PMC: 11566031.
DOI: 10.1101/2024.11.02.621395.
Doi A, Delaney C, Tanner D, Burkhart K, Bell R
Mol Ther Nucleic Acids. 2024; 35(3):102311.
PMID: 39281698
PMC: 11401238.
DOI: 10.1016/j.omtn.2024.102311.
Kjer-Hansen P, Phan T, Weatheritt R
Nat Rev Drug Discov. 2024; 23(10):759-779.
PMID: 39232238
DOI: 10.1038/s41573-024-01025-z.
Buchholz S, Zempel H
Alzheimers Dement. 2024; 20(5):3606-3628.
PMID: 38556838
PMC: 11095451.
DOI: 10.1002/alz.13784.
Facal C, Bessone I, Muniz J, Pereyra A, Pedroncini O, Paez-Paz I
Mol Ther. 2024; 32(4):1080-1095.
PMID: 38310353
PMC: 11163272.
DOI: 10.1016/j.ymthe.2024.01.033.
Pathological and physiological functional cross-talks of α-synuclein and tau in the central nervous system.
Jin M, Wang S, Gao X, Zou Z, Hirotsune S, Sun L
Neural Regen Res. 2023; 19(4):855-862.
PMID: 37843221
PMC: 10664117.
DOI: 10.4103/1673-5374.382231.
Vascular endothelial growth factor isoforms differentially protect neurons against neurotoxic events associated with Alzheimer's disease.
Alalwany R, Hawtrey T, Morgan K, Morris J, Donaldson L, Bates D
Front Mol Neurosci. 2023; 16:1181626.
PMID: 37456522
PMC: 10349181.
DOI: 10.3389/fnmol.2023.1181626.
Disrupting pathologic phase transitions in neurodegeneration.
Hurtle B, Xie L, Donnelly C
J Clin Invest. 2023; 133(13).
PMID: 37395272
PMC: 10313377.
DOI: 10.1172/JCI168549.
Tau protein binds to the P53 E3 ubiquitin ligase MDM2.
Sola M, Rendon-Angel A, Rojo Martinez V, Sgrignani J, Magrin C, Piovesana E
Sci Rep. 2023; 13(1):10208.
PMID: 37353565
PMC: 10290082.
DOI: 10.1038/s41598-023-37046-8.
SMaRT modulation of tau isoforms rescues cognitive and motor impairments in a preclinical model of tauopathy.
Muniz J, Facal C, Urrutia L, Clerici-Delville R, Damianich A, Ferrario J
Front Bioeng Biotechnol. 2022; 10:951384.
PMID: 36277399
PMC: 9581281.
DOI: 10.3389/fbioe.2022.951384.
RNA-based therapeutics for neurological diseases.
Anthony K
RNA Biol. 2022; 19(1):176-190.
PMID: 35067193
PMC: 8786337.
DOI: 10.1080/15476286.2021.2021650.
Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease.
Carroll T, Guha S, Nehrke K, Johnson G
Biology (Basel). 2021; 10(10).
PMID: 34681146
PMC: 8533264.
DOI: 10.3390/biology10101047.
Fyn knockdown prevents levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Bordone M, Damianich A, Bernardi M, Eidelman T, Sanz-Blasco S, Gershanik O
eNeuro. 2021; .
PMID: 34099487
PMC: 8281260.
DOI: 10.1523/ENEURO.0559-20.2021.
Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology.
Cho J, Kim Y, Rafikian E, Yang M, Santa-Maria I
Front Behav Neurosci. 2021; 15:634157.
PMID: 34093145
PMC: 8175658.
DOI: 10.3389/fnbeh.2021.634157.
Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease.
Karki H, Jang Y, Jung J, Oh J
J Nanobiotechnology. 2021; 19(1):72.
PMID: 33750392
PMC: 7945670.
DOI: 10.1186/s12951-021-00814-7.
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer's Disease.
Kang Y, Diep Y, Tran M, Cho H
Int J Mol Sci. 2020; 21(24).
PMID: 33339351
PMC: 7766709.
DOI: 10.3390/ijms21249591.
Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures.
Pampuscenko K, Morkuniene R, Krasauskas L, Smirnovas V, Tomita T, Borutaite V
Mol Neurobiol. 2020; 58(2):658-667.
PMID: 33001416
DOI: 10.1007/s12035-020-02150-7.
Interneuron NMDA Receptor Ablation Induces Hippocampus-Prefrontal Cortex Functional Hypoconnectivity after Adolescence in a Mouse Model of Schizophrenia.
Alvarez R, Pafundo D, Zold C, Belforte J
J Neurosci. 2020; 40(16):3304-3317.
PMID: 32205341
PMC: 7159887.
DOI: 10.1523/JNEUROSCI.1897-19.2020.
Increasing Tau 4R Tau Levels Exacerbates Hippocampal Tau Hyperphosphorylation in the hTau Model of Tauopathy but Also Tau Dephosphorylation Following Acute Systemic Inflammation.
Barron M, Gartlon J, Dawson L, Atkinson P, Pardon M
Front Immunol. 2020; 11:293.
PMID: 32194553
PMC: 7066213.
DOI: 10.3389/fimmu.2020.00293.
Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.
Lauretti E, Pratico D
Expert Opin Ther Targets. 2020; 24(4):319-330.
PMID: 32116063
PMC: 7201870.
DOI: 10.1080/14728222.2020.1737012.